Technical Analysis for CERO - CERo Therapeutics Holdings, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.24 | -4.35% | -0.06 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -5.80% | |
| Stochastic Buy Signal | Bullish | -5.80% | |
| New 52 Week Low | Weakness | -5.80% | |
| Wide Bands | Range Expansion | -5.80% | |
| Oversold Stochastic | Weakness | -5.80% | |
| New 52 Week Closing Low | Bearish | -6.46% | |
| Narrow Range Bar | Range Contraction | -6.46% | |
| New 52 Week Low | Weakness | -6.46% | |
| Wide Bands | Range Expansion | -6.46% | |
| Oversold Stochastic | Weakness | -6.46% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 16 minutes ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Down 5% | about 1 hour ago |
| New 52 Week Low | about 1 hour ago |
| Possible NR7 | about 1 hour ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
CERo Therapeutics Holdings, Inc. Description
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.
Classification
Sector: Other
Industry: Other
Keywords: Cancer Solid Tumors Immune System Immunotherapy Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Lymphoma Virotherapy Hematological Malignancies Adoptive Cell Transfer T Cells Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Therapy Car T Cell Treating Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.8 |
| 52 Week Low | 1.25 |
| Average Volume | 1,357,111 |
| 200-Day Moving Average | 8.28 |
| 50-Day Moving Average | 2.07 |
| 20-Day Moving Average | 1.52 |
| 10-Day Moving Average | 1.38 |
| Average True Range | 0.25 |
| RSI (14) | 26.47 |
| ADX | 27.59 |
| +DI | 31.34 |
| -DI | 21.55 |
| Chandelier Exit (Long, 3 ATRs) | 1.37 |
| Chandelier Exit (Short, 3 ATRs) | 2.01 |
| Upper Bollinger Bands | 1.93 |
| Lower Bollinger Band | 1.12 |
| Percent B (%b) | 0.25 |
| BandWidth | 52.78 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.35 |
| MACD Histogram | 0.0547 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.52 | ||||
| Resistance 3 (R3) | 1.51 | 1.45 | 1.48 | ||
| Resistance 2 (R2) | 1.45 | 1.40 | 1.45 | 1.47 | |
| Resistance 1 (R1) | 1.38 | 1.37 | 1.42 | 1.39 | 1.46 |
| Pivot Point | 1.32 | 1.32 | 1.33 | 1.32 | 1.32 |
| Support 1 (S1) | 1.25 | 1.27 | 1.29 | 1.26 | 1.18 |
| Support 2 (S2) | 1.19 | 1.24 | 1.19 | 1.17 | |
| Support 3 (S3) | 1.12 | 1.19 | 1.16 | ||
| Support 4 (S4) | 1.13 |
